Table 3 Clinical outcomes in the protamine and non-protamine groups
All (n = 160) | Protamine group (n = 92) | Non-protamine group (n = 68) | p value | |
|---|---|---|---|---|
Primary outcome | 16 (10.0) | 4 (4.3) | 12 (17.6) | 0.006 |
In-hospital death | 2 (1.3) | 0 (0.0) | 2 (2.9) | 0.179 |
Myocardial infarction | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
Stent thrombosis | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
Stroke/systemic embolism | 1 (0.6) | 0 (0.0) | 1 (1.5) | 0.425 |
Bleeding requiring blood transfusion | 1 (0.6) | 1 (1.1) | 0 (0.0) | 0.575 |
Vascular access complications | ||||
Hematoma | 12 (7.5) | 3 (3.3) | 9 (13.2) | 0.020 |
Pseudoaneurysm | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
Arteriovenous fistula | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
Surgical repair | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
In-hospital length of stay, (days) | 6.3 ± 6.3 | 4.8 ± 3.7 | 8.4 ± 8.3 | 0.001 |